Cost-effectiveness of fluocinolone acetonide implant versus systemic therapy for noninfectious intermediate, posterior, and panuveitis.

ABSTRACT:

Objective

To evaluate the 3-year incremental cost-effectiveness of fluocinolone acetonide implant versus systemic therapy for the treatment of noninfectious intermediate, posterior, and panuveitis.

Design

Randomized, controlled, clinical trial.

Participants

Patients with active or recently active intermediate, posterior, or panuveitis enrolled in the Multicenter Uveitis Steroid Treatment Trial.

Methods

Data on cost and health utility during 3 years after randomization were evaluated at 6-month intervals. Analyses were stratified by disease laterality at randomization (31 unilateral vs 224 bilateral) because of the large upfront cost of the implant.

Main outcome measures

The primary outcome was the incremental cost-effectiveness ratio (ICER) over 3 years:

SUBMITTER: Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group 

PROVIDER: S-EPMC4178167 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature